The impact of temporary mechanical circulatory support strategies on thrombocytopenia
Authors' conclusion
These results show that the degree of thrombocytopenia depends on MCS device type and is reversible.
Study context
- Population
- Patients on temporary mechanical circulatory support (MCS), excluding platelet transfusions, bleeding complications, etc.77 analysed
- Participants
- 337 patients
- Exposure
- Temporary MCS strategies: Impella 5.5, VV ECMO, VA ECMO, Intra-aortic Balloon Pump (IABP), Centrimag Biventricular Assist Device (BIVAD)
- Outcome
- Mean percent platelet drop on MCS implantation
Methodological detailsrepeated measure mixed effect and linear regression models
- Repeated measure mixed effect and linear regression models
Main finding
As reported in the abstract
Mean percent platelet drop on implantation
| Group | Value | p |
|---|---|---|
| VA ECMO | mean −69.6% | p < 0.001 |
| VV ECMO | mean −40.9% | p < 0.001 |
| Impella 5.5 | mean −20.9% | p = 0.01 |
| IABP | mean −28.3% | p = 0.01 |
| Centrimag BIVAD | mean −6.5% | p = 0.61 |
Value
VA ECMOmean −69.6%
VV ECMOmean −40.9%
Impella 5.5mean −20.9%
IABPmean −28.3%
Centrimag BIVADmean −6.5%
p
VA ECMOp < 0.001
VV ECMOp < 0.001
Impella 5.5p = 0.01
IABPp = 0.01
Centrimag BIVADp = 0.61
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Platelet recovery after MCS explantationRecovery to or above baseline | VA ECMO +107.0% · p p = 0.42 · Impella 5.5 +117.2% · p p = 0.28 · IABP +108.3% · p p = 0.37 · VV ECMO 163.3% · p p = 0.01* · Centrimag BIVAD +100.1% · p p = 0.99 |
Original publication
The impact of temporary mechanical circulatory support strategies on thrombocytopenia. J Crit Care. Published 23 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →